Scarica l'app Stockscreener
8.26
2.36%
-0.20
Precedente Chiudi:
$8.46
Aprire:
$8.25
Volume 24 ore:
586.84K
Relative Volume:
0.61
Capitalizzazione di mercato:
$426.32M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-2.2003
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
-1.20%
1M Prestazione:
-5.60%
6M Prestazione:
-14.40%
1 anno Prestazione:
+0.73%
Intervallo 1D:
$8.205
$8.78
Intervallo di 1 settimana:
$7.74
$8.78
Portata 52W:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.26 | 436.65M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRT - GlobeNewswire Inc.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD - PR Newswire
Momentum Shift: Can REGENXBIO Inc deliver consistent dividendsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Panic Selling: Is REGENXBIO Inc impacted by rising ratesQuarterly Trade Review & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Sahm
Stop Loss: Is REGENXBIO Inc impacted by rising ratesWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - PharmiWeb.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - The Norfolk Daily News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - ChartMill
Patient centric approach drives AFFINITY DUCHENNE study expansion at REGENXBIO - Traders Union
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio says its gene therapy for muscle disorder showed no evidence of liver injury in study - MSN
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: LEVI & KORSINSKY, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - Sahm
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co. - MarketBeat
RGX-111 Security Concerns Approaching April 14 Cutoff: Legal Resolution or Trigger for Market Decline? - Bitget
REGENXBIO Inc. Files Form 8-K Announcing Material Definitive Agreement – Company Information and NASDAQ Listing Details - Minichart
Form 8K Regenxbio Inc For: 20 March By Investing.com - Investing.com Australia
Regenxbio reaches $10 million settlement with GlaxoSmithKline over sublicense fees - Investing.com
Form 8K Regenxbio Inc For: 20 March - Investing.com
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Regenxbio Inc has officially signed a settlement and release agreement with pharmaceutical giant GlaxoSmithKline. - Bitget
Regenxbio enters settlement and release agreement with GlaxoSmithKline on March 18, 2026SEC filing - marketscreener.com
According to a document submitted to the U.S. Securities and Exchange Commission, biotechnology company Regenxbio Inc has confirmed that it will continue, under its existing sublicensing agreement with pharmaceutical giant GlaxoSmithKline, to pay the l - Bitget
RegenXBio Reaches Settlement with GSK Over License Fees - TipRanks
Regenxbio Settles GSK Sublicense Fee Dispute With $10 Million Payment and Mutual Releases - TradingView
REGENXBIO (NASDAQ: RGNX) agrees $10M settlement payment to GSK - Stock Titan
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch - TradingView
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit – Company Announcement - Financial Times
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action - PharmiWeb.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - marketscreener.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP - Finviz
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
RGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):